Resistance: latest news

Resistance resources

  • My drugs chart

    My drugs chart provides information on all the anti-HIV drugs currently licensed for use in Europe.Select your chosen drugs and drag them onto the area...

    From: My drugs chart

  • What is drug resistance?

    One of the possible consequences of not taking your HIV treatment properly is that your HIV will develop resistance to anti-HIV drugs. This section of the booklet provides...

    From: Booklets

    Information level Level 2
  • Taking your HIV treatment

    This booklet is a starting point for anyone who wants to know about treatment for HIV. It provides basic information about how HIV treatment works...

    From: Booklets

    Information level Level 2
  • Drug resistance

    It's important to always take your HIV treatment at the right times and in the right amounts. If you don't, HIV may become drug resistant.When...

    From: The basics

    Information level Level 1
  • An HIV treatment journey

    This illustrated leaflet shows the journey a lot of people go on with HIV treatment. It involves the decision to start treatment, problems with side...

    From: The basics

    Information level Level 1
  • Drug resistance

    HIV reproduces in the body very quickly, making billions of new viruses every day by replicating its genetic material. HIV is a retrovirus; retroviruses have an inherently high...

    From: HIV treatments directory

    Information level Level 4

Resistance in your own words

Resistance news from aidsmap

More news

Resistance news selected from other sources

  • Think the Aids epidemic is over? Far from it – it could be getting worse

    The 2000 Aids conference in Durban shocked the world into action. Now, a new crisis looms, one fuelled by drug resistance, costly treatments and the lack of power many women have in sexual relationships.

    31 July 2016 | The Guardian
  • Hope for 'end of Aids' is disappearing, experts warn

    Those fighting epidemic say 2030 target is unrealistic as efforts to defeat it falter amid rising infection levels and drug resistance.

    31 July 2016 | The Guardian
  • WHO flags key challenges to global HIV response at International AIDS Conference

    The World Health Organization is highlighting the need to renew attention to HIV prevention, whilst maintaining momentum on scaling up access to HIV treatment. It is also signalling the growing emergence of antiretroviral (ARV) drug resistance and the need for sustainable financing of the global response.

    17 July 2016 | WHO
  • Outbreak of high level azithromycin resistant gonorrhoea in England

    There have been 34 cases of high level azithromycin resistant gonorrhoea amongst residents of England between November 2014 and April 2016. The outbreak spread from the north of England to the West Midlands and south of England, including London. Initial cases were among heterosexuals but more recent evidence suggests high level azithromycin resistant gonorrhoea is now spreading among men who have sex with men.

    15 April 2016 | Public Health England
  • Nigerian herbal medicines widely used by HIV positive people can contain antiretrovirals

    Herbal medicine use among HIV positive people in Nigeria is widespread, poorly recorded and often precedes ART initiation. Contamination with antiretrovirals is possible and concerning, particularly in untreated people, say the authors of a study of herbal medicine presented at CROI 2016.

    24 March 2016 | HIV i-Base
  • Dr. Robert Grant weighs in after the first case of failed PrEP: What does it mean?

    At CROI today, researchers and providers heard a detailed case study of a man who was infected with drug-resistant HIV while taking PrEP. No study to date has definitively documented a “breakthrough” HIV infection during PrEP with adherence to Truvada, so the report has garnered a lot of attention and concern from community members. We spoke with Robert Grant, MD, MPH, to give context to the discussion about what this case means for people currently taking PrEP.

    26 February 2016 | BETA blog
  • What is a drug “tail,” and what does it have to do with long-acting PrEP?

    Drug “tails” are a hot topic at CROI 2016 as attendees wait to hear results from a long-acting cabotegravir PrEP injection study with HIV-negative men. A few prominent researchers have already incorporated the issue of drug “tails” into their discussions of one potential downside to having a PrEP drug that stays in a person’s system for an extended length of time.

    25 February 2016 | BETA blog
  • HIV and drug resistance

    A recent study found more resistance to the antiretroviral medicine tenofovir than had previously been reported, with 20% resistance to tenofovir in patients with treatment failure in Europe and over 50% resistance in patients with treatment failure in sub-Saharan Africa... The study underlines the importance of rapidly identifying treatment failure through routine measurement of viral load suppression—this is the basis of the third pillar of UNAIDS’ 90–90–90 treatment target, that 90% of people accessing HIV treatment have suppressed viral loads.

    09 February 2016 | UNAIDS
  • HIV resistance to favored treatment not uncommon

    Resistance to a key HIV drug is common worldwide and could mean trouble for treating and preventing the virus that causes AIDS, according to a new study.

    29 January 2016 | Reuters
  • Undetectable & Low-level HIV Viral Replication

    Even people who are adherent to their medication regimens may experience occasional “blips” in their viral loads, experience viral rebound or maintain a steady, if low, viral load above undetectable levels. To understand why some people struggle to achieve or remain undetectable, we spoke with Keith Henry, MD, an HIV specialist at Hennepin County Medical Center who has more than 25 years of experience caring for people with HIV.

    06 January 2016 | BETA blog
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close